|
1
|
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.
|
Ann Rheum Dis
|
2009
|
3.32
|
|
2
|
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
|
Ann Rheum Dis
|
2011
|
2.74
|
|
3
|
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
|
J Rheumatol
|
1999
|
2.21
|
|
4
|
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
|
Ann Rheum Dis
|
2005
|
2.08
|
|
5
|
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.
|
Ann Rheum Dis
|
2002
|
2.02
|
|
6
|
Treatment recommendations for psoriatic arthritis.
|
Ann Rheum Dis
|
2008
|
1.85
|
|
7
|
A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis.
|
J Rheumatol
|
1999
|
1.40
|
|
8
|
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.
|
Ann Rheum Dis
|
2003
|
1.31
|
|
9
|
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year.
|
J Rheumatol
|
1999
|
1.31
|
|
10
|
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
|
Arthritis Rheum
|
2007
|
1.21
|
|
11
|
Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis.
|
Ann Rheum Dis
|
2004
|
1.21
|
|
12
|
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.
|
Clin Exp Rheumatol
|
2011
|
1.19
|
|
13
|
Osteoporosis in rheumatoid arthritis and ankylosing spondylitis.
|
Clin Exp Rheumatol
|
2009
|
1.10
|
|
14
|
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
|
Ann Rheum Dis
|
2006
|
1.05
|
|
15
|
Costs of ankylosing spondylitis in three European countries: the patient's perspective.
|
Ann Rheum Dis
|
2003
|
0.99
|
|
16
|
Evidence for a differential association of the Arg200Trp single-nucleotide polymorphism in FRZB with hip osteoarthritis and osteoporosis.
|
Rheumatology (Oxford)
|
2005
|
0.96
|
|
17
|
Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis.
|
Ann Rheum Dis
|
2002
|
0.96
|
|
18
|
Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists.
|
Ann Rheum Dis
|
2007
|
0.94
|
|
19
|
Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order.
|
Ann Rheum Dis
|
2004
|
0.89
|
|
20
|
Association between ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis: reality or fiction?
|
Clin Exp Rheumatol
|
1996
|
0.82
|
|
21
|
Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment.
|
Clin Exp Rheumatol
|
2008
|
0.81
|
|
22
|
Non-Hodgkin's lymphoma presenting with spinal involvement.
|
Ann Rheum Dis
|
2000
|
0.78
|
|
23
|
Influence of human recombinant interleukin-1 beta on human articular cartilage. Mitotic activity and proteoglycan metabolism.
|
Clin Exp Rheumatol
|
1991
|
0.78
|
|
24
|
Reliability of self assessed joint counts in ankylosing spondylitis.
|
Ann Rheum Dis
|
2002
|
0.76
|
|
25
|
Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis.
|
Ann Rheum Dis
|
2009
|
0.76
|
|
26
|
Images in rheumatology: cervical septic spondylodiscitis in association with diffuse idiopathic skeletal hyperostosis.
|
J Rheumatol
|
1999
|
0.75
|